Alnylam Pharmaceuticals Inc (ALNY)vsKyverna Therapeutics, Inc. Common Stock (KYTX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
KYTX
Kyverna Therapeutics, Inc. Common Stock
$7.64
-3.17%
HEALTHCARE · Cap: $470.30M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
KYTX
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for KYTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : KYTX
The strongest argument for KYTX centers on Debt/Equity, Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : KYTX
The primary concerns for KYTX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while KYTX is a value play — different risk/reward profiles.
KYTX carries more volatility with a beta of 3.35 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 26/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Kyverna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kyverna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced immunotherapies for autoimmune diseases and serious medical conditions. Utilizing its cutting-edge genetically engineered T-cell technology, the firm aims to enhance the immune system's capabilities, offering targeted solutions for effective disease management. With a strategic focus on cellular therapies, Kyverna is well-positioned within the biopharmaceutical sector, presenting compelling opportunities for institutional investors looking to support transformative treatments and capitalize on growth in the immunotherapy landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?